Highest-materiality recent filing
Petros Pharmaceuticals grants 7M restricted shares to Chairman, two directors, and President
Aggregate 7,000,000 restricted shares granted to Joshua Silverman (Chairman), Bruce Bernstein, Fady Boctor, and Wayne Walker.
Petros Pharmaceuticals grants 7.25M RSUs to executives and directors; 50% vested immediately
Joshua Silverman (Chairman) receives 4,375,000 RSUs; Bruce Bernstein 1,875,000; Fady Boctor 500,000; Wayne Walker 500,000.
Nasdaq notifies Petros Pharmaceuticals of common stock delisting effective Nov 7, 2025
Nasdaq notified Petros on Nov 3, 2025, of intention to delist common stock on Nov 7, 2025.
Petros Pharmaceuticals assigns subsidiary assets (Metuchen, Timm, Pos-T-Vac) to creditor trust
Effective June 16, 2025, Petros assigned all assets of subsidiaries Metuchen, Timm Medical, and Pos-T-Vac to a third-party fiduciary for benefit of creditors.
Petros Pharma receives Nasdaq delisting notice; trading to move to OTC Markets
Delisting due to failing minimum equity, bid price ($1.00), and public interest concerns from Feb 2025 offering.
Nasdaq notified Petros on April 28 of public interest concerns regarding its February 19, 2025 public offering as a new delisting basis under Rule 5810(d).
Nasdaq notified Petros on Apr 8 it fails $2.5M minimum stockholders' equity requirement, adding to existing bid price deficiency.
Company terminated Marcum LLP as auditor on April 5, 2025, and engaged CBIZ CPAs P.C. as new independent auditor for FY 2025.
Petros Pharmaceuticals Prices $9.6 Million Public Offering of Common Stock and Warrants
Petros Pharmaceuticals entered securities purchase agreement for 13,950,012 units and 26,049,988 pre-funded units at $0.24 and $0.2399 per unit.
Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.
Metuchen failed to pay installment due Oct 1, 2024; all obligations accelerated.
Petros Pharma stockholders OK reverse stock split up to 1:25
Directors Silverman, Bernstein, Walker elected to one-year terms.
Petros Pharmaceuticals dismisses EisnerAmper as auditor, appoints Marcum; cites material weaknesses
Audit committee dismissed EisnerAmper as independent auditor on January 8, 2024; engaged Marcum effective immediately.
On October 1, 2024, John Shulman, who served as a member of the board of directors (the “Board”) of Petros Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as director of the Company, effective as of October 1, 2024.
On October 2, 2024, Greg Bradley, who served as a member of the Board tendered his resignation from his role as director of the Company, effective as of October 2, 2024.
Max materiality 0.90 · Median 0.60 · Most common event other_material